Rinvoq Alternatives Compared
| Rinvoq (upadacitinib) | Humira (adalimumab) | Methotrexate |
|
|---|
| Rinvoq (upadacitinib) | Humira (adalimumab) | Methotrexate |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Crohn's Disease, Ankylosing Spondylitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Giant Cell Arteritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Methotrexate may be considered for the treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), mycosis fungoides, and certain cancers, such as ALL or... View more |
Related suggestions Rheumatoid Arthritis
Polyarticular Juvenile Idiopathic Arthritis
Popular comparisons
|
|||||||||||||||||||||||
| More about Rinvoq (upadacitinib) | More about Humira (adalimumab) | More about Methotrexate | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Rinvoq has an average rating of 7.1 out of 10 from a total of 240 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 16% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 704 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
Methotrexate has an average rating of 6.5 out of 10 from a total of 339 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Rinvoq side effects |
View all Humira side effects |
View all Methotrexate side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Rinvoq prices |
View all Humira prices |
View all Methotrexate prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other upadacitinib brands include: Rinvoq LQ | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Jylamvo, Methotrexate LPF Sodium, Otrexup, Rasuvo, Trexall, Xatmep | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
14 hours |
480 hours |
15 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 616 drugs are known to interact with Rinvoq:
|
A total of 556 drugs are known to interact with Humira:
|
A total of 732 drugs are known to interact with Methotrexate:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 16, 2019 |
December 31, 2002 |
December 07, 1953 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.